While a huge amount of attention is being directed at crypto and media these days, one of the most important wild card investment trends of the 2020s is the coming expansion of biotech. Democratized science tools, improved research networking, and lab automation will revolutionize the practice of biotech, and that means there are huge opportunities for intrepid founders. But there’s a catch: biotech stock performance has been abysmal the past year, and many investors are walking away from the market. Josh Wolfe joins Danny Crichton to talk about what the gyrations in the biotech markets means for startups, some developments around the Human Genome Project, and what strategies existing biotech firms can take to weather the coming consolidation and reinvention of the industry.
